Abstract
OBJECTIVE: To evaluate the efficacy and safety of methotrexate in chronic
actinic dermatitis.
METHODS: Clinically and biopsy proven cases of chronic actinic dermatitis
were included in study after fulfilling the inclusion criteria. Patients were given
methotrexate according to protocol and efficacy was noted according to
improvement in Psoriasis Area and Severity Index (PASI) score. Side effects
were noted for safety evaluation.
RESULTS: A total of thirty patients, 27 male and 3 females, with a mean age of
57.5±9.91 years, were included in study. Duration of disease was <1year in 5
patients, 2-5 years in 14 patients, 6-10 year in 8 patients and >10 years in 6 patients.
Twenty seven patients received 10mg and 3 patients received dose of
15mg.Twenty nine patients completed 6 months of methotrexate therapy. One
patient stopped treatment because of mild gastrointestinal side effects and
deranged liver function tests (LFTs). Serum glutamic pyruvic transaminase (SGPT)
was 3 time above normal when treatment was stopped. Patients were evaluated at
st th 1 week, 4 week and monthly for 6 months. Six patients (20%) showed complete
recovery, 13 (43%) showed 50-75% recovery, 7 (23%) showed 25-49%
recovery while rest showed no improvement. Means of initial and final PASI score
showed significant results with P<0.0001. The clinical response to treatment was
observed at 4-6 weeks which reached to maximum in 4-6 months.
CONCLUSION: We found methotrexate to be a potentially efficacious and
safe drug in the treatment and a steroid sparing drug in chronic actinic dermatitis.
Mohammad Majid Paracha, Sahibzada Mahmood Noor, Irfanullah, Ghafoorullah, Abdul Qayum Khan. (2018) EFFICACY AND SAFETY OF METHOTREXATE IN CHRONIC ACTINIC DERMATITIS: A PILOT STUDY, KHYBER MEDICAL UNIVERSITY JOURNAL, Volume 10, Issue 3.
-
Views
934 -
Downloads
100
Article Details
Volume
Issue
Type
Language
Received At
Accepted At
